Innodem Neurosciences

📍 Montreal, Canada👥 12 employees💰 Last funded Sep 2025
Innodem Neurosciences is committed to improving the effectiveness and quality of life and care of patients with neurological problems. Innodem works with the pharmaceutical industry, leading medical professionals, and artificial intelligence experts to develop and promote Eye Movement Biomarkers (EMBs) & Gaze Mapping Biomarkers (GMBs) as important clinical assessment tools in the field of neurology. It is building a series of disease-specific tests embodied in an intuitive App that captures EMB & GMB data. The vision is that over time, while leveraging the latest advances in machine and deep learning, this EMB/GMB platform will assist users to accurately diagnose and monitor neurological disorders affecting eye-movements or cognition such as multiple sclerosis, Alzheirmer’s, Parkinson’s or related disorders, Frontotemporal dementia, Cancer-related cognitive impairment (Chemo Brain) and many others.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
Founded
Investor geography2 countries
United States
2
Canada
1
Investor activity2021–2025 · investors recorded per year
202112023120251
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Innodem Neurosciences?
Innodem Neurosciences has 3 investors on record on gritt.io.
When did Innodem Neurosciences last raise funding?
The most recent investment in Innodem Neurosciences recorded on gritt.io was in September 2025.
What industry is Innodem Neurosciences in?
Innodem Neurosciences operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is Innodem Neurosciences based?
Innodem Neurosciences is headquartered in Montreal, Canada.